Maintaining Safety with SARS-CoV-2 Vaccines

Maintaining Safety with SARS-CoV-2 Vaccines

The vast majority of people who have received the Covid-19 vaccine to date have had self-limited local or low-grade systemic reactions that resolve within 2 or 3 days. A very small number of people have had serious anaphylactic reactions requiring catecholamine infusion and respiratory support. It i...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 384; no. 7; pp. 643 - 649
Main Authors: Castells, Mariana C, Phillips, Elizabeth J
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 18-02-2021
Subjects:
Allergies
Anaphylaxis
Anaphylaxis - etiology
Anaphylaxis - therapy
Antigens
Catecholamines
Clinical trials
COVID-19
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - adverse effects
COVID-19 Vaccines - immunology
Drug dosages
Humans
Hypersensitivity (immediate)
Immunization
Injections
Lipids
mRNA Vaccines
Nanoparticles
Polyethylene glycol
Review
Severe acute respiratory syndrome coronavirus 2
Vaccines
Vaccines, Synthetic - adverse effects
Vaccines, Synthetic - immunology
Viral Vaccines - adverse effects
Viral Vaccines - immunology
Workers
United Kingdom > UK
United States > US
Alaska
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The vast majority of people who have received the Covid-19 vaccine to date have had self-limited local or low-grade systemic reactions that resolve within 2 or 3 days. A very small number of people have had serious anaphylactic reactions requiring catecholamine infusion and respiratory support. It is important to survey patients in advance of vaccination for allergic responses and to be aware of the early signs of an immediate hypersensitivity reaction.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMra2035343